FDA Approves Gene Therapy for Genetic Hearing Loss, Offering Free Treatment
The Food and Drug Administration (FDA) has approved Otarmeni, a gene therapy developed by Regeneron, for a rare form of inherited hearing loss. This therapy targets children and adults with OTOF-related deafness, a condition caused by a mutation in the OTOF gene, which is crucial for hearing. The approval follows a clinical trial involving 20 children, where 16 showed hearing improvement after receiving the therapy. The treatment, which involves a single injection into the cochlea, is reported to be generally safe with no major side effects. Regeneron has announced that the therapy will be provided free of charge to U.S. patients, highlighting the company's commitment to making biopharmaceutical advancements accessible. 
